<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

News

External stories on biodesix

Posts in: molecular diagnostic

Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial (Xconomy)

Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.

A Better Route for Diagnostics? (Drug Discovery & Development)

The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.

Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)

Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.

Getting Personal (Clinical Lab Products)

Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.

Biodesix Targeting Pharma for VeriStrat (GenomeWeb)

Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.

Blood Test Helps Target Roche/OSI Lung Cancer Drug (Reuters)

Testing for a specific cancer protein markers in lung cancer patients' blood helps find those more likely to respond to Tarceva, a drug sold by Roche.

CBSA BioBreakfast Focuses on Two CO Success Stories of 2009 (Rocky Radar)

CBSA's May BioBreakfast allowed two of Colorado's 2009 Bioscience success stories to share their stories. First up was Biodesix, in the diagnostic space.

Video Highlights from 2nd European Lung Cancer Conference Feature Biodesix Serum Test

Presenting current issues with lung cancer tissue testing, followed by a discussion of Veristrat, Biodesix proteomic serum test for predicted tumor response

New Blood Test May Help in the Fight Against Lung Cancer (Queen’s University)

A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively.

Biodesix: a New Way to Inform Cancer Treatment Selection (Rocky Radar)

One data point doesn't tell you very much in most cases. This principle guides Biodesix's approach to developing diagnostics.